Global continuous glucose monitoring (CGM) company Dexcom, Inc. and Kakao Healthcare announced that they held a joint academic symposium, "DynamiK Symposium," for domestic medical professionals in Seoul on February 26th and in Busan on February 27th. This event, the first joint academic event since the two companies officially launched their partnership in January 2026, was designed to share the latest clinical evidence on diabetes management using CGM and data utilization methods based on digital platforms.
The symposium, held over two days in Seoul and Busan, was attended by domestic endocrinology experts and Professor Halis Akturk of the Department of Endocrinology at the University of Colorado School of Medicine in the United States. The lecture presented research results showing that the use of real-time CGM (rtCGM) has shown clinical effects such as reducing glycated hemoglobin (A1C), increasing the time in the target blood glucose range (TIR), and reducing the time of hyperglycemia (TAR). In particular, the 'DIaMonD Study (T2D)' and the 'MOBILE Study' reported cases of short-term improvement in blood glucose control after the application of rtCGM in patients with type 2 diabetes.
An analysis utilizing domestic patient data also highlighted that rtCGM use contributes to improved A1C and increased TIR, and is expected to result in long-term medical cost savings. Professor Kim Jae-hyun of the Department of Endocrinology and Metabolism at Samsung Medical Center, Sungkyunkwan University, announced that through an economic evaluation tailored to the domestic environment, the introduction of rtCGM was confirmed to be a cost-effective option for patients with type 2 diabetes who require multiple daily insulin injections (MDIs) and basal insulin therapy.
The Dexcom G7 device continuously measures blood glucose levels through a skin-attached sensor and provides real-time notifications and pre-warning features for hypoglycemia, enabling patients to respond quickly. This symposium shared the G7's accuracy, clinical performance, and the impact of its "Urgent Low Soon" alert feature on healthcare professionals and patient management.
“CGM is a key tool for improving access to diabetes management and shifting the treatment paradigm,” said Jennifer Cho, Vice President and General Manager of Dexcom APAC. “By combining Dexcom technology with the Kakao Healthcare platform, we will expand its usability for domestic patients and medical professionals.”
The two companies plan to continue academic exchanges related to CGM through this symposium and to promote treatment accessibility and expand educational programs for domestic diabetes patients.
In the domestic medical device and digital healthcare industries, the number of cases linking CGMs with digital platforms is increasing, and technology adoption is actively underway to improve the accuracy and convenience of diabetes patient management.
You must be logged in to post a comment.